- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT00980551
Pilot Study of Topotecan/Vincristine With Subconjunctival Carboplatin for Patients With Bilateral Retinoblastoma (RELRB1)
A Pilot Study of Intravenous Topotecan and Vincristine in Combination With Subconjunctival Carboplatin for Patients With a History of Bilateral Retinoblastoma and Refractory/Recurrent Intraocular Disease (IND# 104,942)
The investigators are testing subtenon carboplatin in combination with vincristine and topotecan given by vein in the hopes of finding a drug combination that may be effective against retinoblastoma that has come back (recurrent) or is resistant to other treatment (refractory).
The goals of this study are:
- To decide if the drug combination is a useful treatment for recurrent or refractory retinoblastoma
- To test the safety of the drug combination and to see what kind of effects (good and bad) can be expected from the drug combination
- To measure visual changes before and after the study therapy
- To use a special MRI scan to measure brain function involved in vision processing, both before and after the study therapy
In this study, the investigators are also testing a new experimental way of giving carboplatin "subtenon carboplatin". The carboplatin will be given directly in the eye through a needle placed under the covering of the eye. This is to try to get more carboplatin to the retinoblastoma inside the eye.
Panoramica dello studio
Stato
Condizioni
Intervento / Trattamento
Tipo di studio
Fase
- Non applicabile
Contatti e Sedi
Luoghi di studio
-
-
Ohio
-
Cincinnati, Ohio, Stati Uniti, 45229
- Cincinnati Children's Hospital Medical Center
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
- Age: ≤ 10 years of age
- Diagnosis: Patients must have a history of bilateral Retinoblastoma AND Recurrent/Refractory Intra-Ocular Retinoblastoma considered not amenable to cure with local therapies alone (photocoagulation with argon laser, cryotherapy, transpupillary thermotherapy, radioactive plaque therapy).
- Therapeutic Options: Patient's disease status is one for which there are no known options proven to provide a high chance for ocular salvage or cure other than external beam radiation or enucleation.
- Remaining visual function in target eye (s) is required
- Life Expectancy of > 8 weeks
- Lansky ≥ 50
- Prior Therapy: Patients must have local relapsed/refractory disease after receiving standard upfront therapy involving at least one chemotherapeutic regimen. There is no limit to prior chemotherapeutic regimens permitted. Patients may have received previous intravenous carboplatin, but may not have received prior subtenon carboplatin or intravenous topotecan.
Patients must have recovered from the acute toxic effects of all prior chemotherapy, immunotherapy, or radiotherapy prior to entering this study, as described below:
- Myelosuppressive chemotherapy: patients must not have received myelosuppressive chemotherapy within 3 weeks of study enrollment
- Biologic therapies: Patients must not have received biologic anti-cancer agents within one week of study enrollment
- Radiation therapy: Four weeks must have elapsed since external beam radiation therapy, if given.
Adequate Bone Marrow Function Defined as:
- Peripheral absolute neutrophil count (ANC) ≥ 750/µL
- Platelet count ≥ 75,000/µL (transfusion independent, defined as not receiving platelet transfusions within a 7-day period prior to enrollment)
- Hemoglobin ≥ 8.0 gm/dL (may receive RBC transfusions)
Adequate Renal Function Defined as:
- Creatinine clearance or radioisotope GFR ≥ 70ml/min/1.73 m2 OR threshold creatinine values based on age/gender derived from the Schwartz formula for estimating GFR
Adequate Liver Function Defined As:
- Bilirubin (sum of conjugated + unconjugated) ≤ 1.5 x upper limit of normal (ULN) for age
- SGPT (ALT) ≤ 5 x upper limit of normal (ULN) for age
- Serum albumin ≥ 2 g/dL
Exclusion Criteria:
- Extra-ocular retinoblastoma
- Asynchronous involvement of the contralateral eye, previously untreated
- Uncontrolled infection at time of protocol entry
Concomitant Medications:
- Growth factors that support platelet or white cell number or function must not have been administered within the past 3 days
- Patients who are currently receiving investigational drugs, or who have received an investigational drug within the last 7 days, are ineligible
- Patients who are currently receiving other anti-cancer agents are ineligible
- Patients who in the opinion of the investigator may not be able to comply with the safety monitoring requirements of the study are not eligible
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: N / A
- Modello interventistico: Assegnazione di gruppo singolo
- Mascheramento: Nessuno (etichetta aperta)
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
---|---|
Sperimentale: Topotecan/Vincristine with subtenon Carboplatin
|
Available in 50mg, 150mg, 450 mg, 600mg vials.
It is provided as a premixed aqueous solution or lyophilized powder for injection given on day 1/week 10 (cycles 1-3).
Altri nomi:
Each vial contains topotecan hydrochloride equivalent to 4 mg of topotecan as free base.
Given intravenously on days 1-5 of each week (cycles 1-6).
Altri nomi:
Each vial contains vincristine sulfate, 1 mg; mannitol, 100 mg; sterile water for injection; Acetic acid and sodium acetate are added for pH control.
Given intravenously on day 1/week 1 (cycles 1-6).
Altri nomi:
Supplied as a clear solution in 300 mcg/ml 1 ml or 1.6 ml vials and prefilled syringes containing 300mcg/0.5mL
or 480mcg/0.8mL.
Given intravenously on day 6 of each week (cycles 1-6).
Altri nomi:
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Lasso di tempo |
---|---|
To estimate the event-free survival, where an event is defined at the ocular level as the need for non-protocol therapy defined as additional non-protocol chemotherapy, external beam radiation, or enucleation.
Lasso di tempo: at 1 year
|
at 1 year
|
To estimate the patterns of response, and response rate of locally refractory retinoblastoma to combination intravenous and peri-ocular chemotherapy.
Lasso di tempo: at 1 yr
|
at 1 yr
|
Misure di risultato secondarie
Misura del risultato |
Lasso di tempo |
---|---|
To describe the toxicities associated with the proposed regimen.
Lasso di tempo: at 1 yr
|
at 1 yr
|
To describe the histologic findings in the eyes ultimately requiring enucleation.
Lasso di tempo: at 1 yr
|
at 1 yr
|
To describe the visual acuity of patients with advanced intraocular retinoblastoma before and after the proposed therapy.
Lasso di tempo: at 1 yr
|
at 1 yr
|
To describe primary visual cortex function in patients with retinoblastoma via functional Magnetic Resonance Imaging (fMRI) technique both before and after the proposed therapy.
Lasso di tempo: at 1 yr
|
at 1 yr
|
Collaboratori e investigatori
Investigatori
- Investigatore principale: James Geller, MD, Children's Hospital Medical Center, Cincinnati
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Completamento primario (Effettivo)
Completamento dello studio (Effettivo)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Stima)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Termini MeSH pertinenti aggiuntivi
- Neoplasie per tipo istologico
- Neoplasie
- Neoplasie per sede
- Neoplasie, ghiandolari ed epiteliali
- Malattie degli occhi
- Malattie retiniche
- Neoplasie, Neuroepiteliali
- Tumori neuroectodermici
- Neoplasie, cellule germinali ed embrionali
- Neoplasie, tessuto nervoso
- Malattie degli occhi, ereditarie
- Neoplasie oculari
- Neoplasie retiniche
- Retinoblastoma
- Meccanismi molecolari dell'azione farmacologica
- Inibitori enzimatici
- Agenti antineoplastici
- Modulatori della tubulina
- Agenti antimitotici
- Modulatori della mitosi
- Agenti antineoplastici, fitogenici
- Inibitori della topoisomerasi
- Inibitori della topoisomerasi I
- Carboplatino
- Vincristina
- Topotecan
Altri numeri di identificazione dello studio
- RELRB1
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .
Prove cliniche su subtenon Carboplatin
-
Claudia ProtoAttivo, non reclutanteCarcinoma del timo | TimomaItalia
-
Mahidol UniversitySconosciutoInfiammazione | Pressione intraoculareTailandia
-
Zhimin ShaoRoche Pharma AGSconosciutoCancro al seno positivo per HER-2Cina
-
Yeungnam University College of MedicineCompletatoOcclusione della vena retinica del ramoCorea, Repubblica di
-
Virginia Commonwealth UniversityNational Cancer Institute (NCI)RitiratoStadio IIIA Carcinoma polmonare non a piccole cellule | Stadio IIIB Carcinoma polmonare non a piccole cellule | Cancro polmonare a cellule squamose | Adenocarcinoma del polmone | Cancro polmonare a grandi cellule | Stadio IIA Carcinoma polmonare non a piccole cellule | Carcinoma polmonare non a...
-
Sameh FathyCompletato
-
University of California, IrvineNatera, Inc.Non ancora reclutamentoAdenocarcinoma gastroesofageoStati Uniti
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletatoTumore cerebrale | Tumore del sistema nervoso centraleStati Uniti, Canada, Australia, Svizzera, Olanda, Nuova Zelanda